We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Hydroxycitrate Potentially More Effective Than Citrate for Kidney Stones

By LabMedica International staff writers
Posted on 18 Aug 2016
The chemical hydroxycitrate (HCA) was shown in a recent study to be more effective for treating calcium oxalate kidney stones than the commonly used compound potassium citrate.

Calcium oxalate monohydrate is the principal component of human kidney stones and citrate (CA) is an often-used therapy, but hydroxycitrate (HCA) is not. More...
In a study published in the August 8, 2016, online edition of the journal Nature, investigators at the University of Houston (TX, USA) used techniques of bulk crystallization, in situ atomic force microscopy, and density functional theory to compare the capacity of CA and HCA to prevent or even reverse the growth of calcium oxalate crystals.

The investigators reported finding a mechanism that differed from classical theory in that inhibitor adsorption on crystal surfaces induced dissolution of the crystal under specific conditions rather than merely reducing the rate of crystal growth. This phenomenon occurred even in supersaturated solutions where the inhibitor concentration was three orders of magnitude less than that of the solute.

Decrease in crystal size was explained by a hypothesis, generated from atomic force microscopy observations, that inhibitor–crystal interactions imparted localized strain to the crystal lattice and that oxalate and calcium ions were released into solution to alleviate this strain.

For HCA to function as a kidney stone treatment, it must be excreted in urine. The investigators reported that HCA ingested by non-stone-forming humans at an often-recommended dose led to substantial urinary excretion. In vitro assays using human urine revealed that HCA was as effective an inhibitor of nucleation of calcium oxalate monohydrate nucleation as was CA. These findings supported further exploration of the clinical potential of hydroxycitrate as an alternative treatment to citrate for kidney stones.

Senior author Dr. Jeffrey D. Rimer, associate professor of chemical engineering at the University of Houston, said that, "While this research established the groundwork to design an effective drug, questions remain. Long-term safety, dosage, and additional human trials are needed. But our initial findings are very promising. If it works in vivo, similar to our trials in the laboratory, HCA has the potential to reduce the incidence rate of people with chronic kidney stone disease."

Related Links:
University of Houston


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.